TrovaGene Looks To Revolutionize The Cancer Diagnostic Market
Jason Napodano, CFA • 45 Comments
Jason Napodano, CFA • 45 Comments
Wed, Nov. 30, 9:47 AM
- Trovagene (NASDAQ:TROV) announces it has entered into a long-term Supply and Distribution Agreement with Boreal Genomics, merging their respective technologies to co-develop urine and blood ctDNA assay kits.
- Through this partnership, the companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine and low-cost urine and blood ctDNA assay for next generation sequencing (NGS) platforms. Trovagene (TROV) and Boreal have each contributed proprietary technology and methods to enhance ctDNA detection capabilities from urine and blood to develop a series of cancer-specific multigene panels planned for launch in 2017.
- Features of the partnership include upfront and milestone payments by Trovagene totaling $1M, global distribution and sub-distribution rights in blood and exclusively in urine for at least 10 years.
- Also, Trovagene and Boreal will work together to have the kits and systems manufactured in a cGMP facility, and to take them through FDA, CE Mark, CFDA and other regulatory approval pathways.
Mon, Nov. 28, 12:06 PM
- Results from a 60-sample study assessing the ability to detect EGFR mutations in the plasma and urine in patients with non-small cell lung cancer (NSCLC) using Trovagene's (TROV -3.2%) Precision Cancer Monitoring (PCM) technology showed relatively comparable sensitivity to tissue samples (biopsies) in certain cases.
- In urine samples, the sensitivity was 72% (n=34/47) for the mutation T790M, 75% (n=12/16) for L858R and 67% (n=28/42) for exon 19 deletions, all compared to tissue samples (reference). In high volume (90 - 100 mL) urine samples, the sensitivities improved to 93%, 80% and 83%, respectively, albeit based on smaller sample sizes.
- Comparable sensitivities were observed in plasma samples.
- Together, plasma and urine testing identified 12 additional T790M-positive cases that were either undetectable or inadequate by tissue test.
- The results will be presented in early December at the 17th World Conference on Lung Cancer in Vienna, Austria.
Thu, Nov. 10, 12:43 PM
- Gainers: TUBE +81%. DRYS +61%. ECPG +29%. EBIO +26%. WAC +19%. GNK +19%. FONR +19%. KRNT +19%. MVIS +18%. CLMT +16%. OMER +18%. GSM +17%. INVE +16%. ZLTQ +16%. SHAK +17%. CLCD +15%. TDW +15%. NEOS +14%. SODA +15%. TRVN +14%.
- Losers: ANTH -36%. PMTS -34%. CAG -29%. AVID -27%. RPD -25%. SUNW -22%. HLIT -20%. NVAX -18%. URRE -17%. TROV -16%. GOL -16%. DPRX -16%. RTK -16%. CRMD -16%. HSGX -15%. WUBA -15%. SGNL -15%. QNST -15%. CZZ -13%.
Wed, Nov. 9, 4:19 PM
Tue, Oct. 4, 11:38 AM
- Trovagene (TROV +5.2%) announces that its Trovera liquid biopsy will be part of a pancreatic cancer study called Precision Promise, a large-scale trial designed to explore the use of precision medicine to improve patient outcomes. Non-profit outfit The Pancreatic Cancer Action Network will make an initial investment of $35M to kick-start the effort.
- The company is a founding member of the initial Precision Promise Industry Working Group so it is not surprising to see the inclusion of its liquid biopsy in the study.
- Trovagene's proprietary Precision Cancer Monitoring technology enables the detection and monitoring of circulating tumor DNA in urine and blood.
Wed, Aug. 17, 10:44 AM
- Liquid biopsy firm Trovagene (TROV +2.7%) inks an in-network agreement with Blue Cross Blue Shield of Illinois establishing member access to its full line of tests and services. According to the company, it now has contracts covering ~168M American lives.
- Trovagene's proprietary technology is focused on the detection of cell-free DNA (cfDNA) in urine and blood as a potential method of managing cancer. Its value proposition is a less invasive way to monitor and detect cancer compared to tissue biopsy while being less expensive, more convenient and much more patient-friendly.
Thu, Aug. 4, 4:36 PM
Fri, Jun. 10, 12:48 PM
Fri, Jun. 10, 11:00 AM
Tue, May 10, 4:22 PM
- TrovaGene (NASDAQ:TROV): Q1 EPS of -$0.36 misses by $0.07.
- Revenue of $0.12M (-7.7% Y/Y) misses by $0.14M.
- Shares are up 13% premarket but only on turnover of 1,500 shares.
Mon, May 9, 9:56 AM
- Laboratory Corporation of America (LH +0.9%) launches Epi proColon, the first FDA-approved DNA-based blood test for colorectal cancer (CRC) screening. The product was developed by Epigenomics AG (OTCQX:EPGNF)(OTCQX:EPGNY) and is available under a joint commercialization agreement with Polymedco in North America.
- Epi proColon detects a DNA methylation biomarker for CRC called Septin9 in cell-free DNA circulating in the blood. The FDA approved it on April 13.
- CRC screening-related tickers: (EXAS +3.7%)(VNRX +0.3%)(TBIO +9.6%)(SQNM +1.8%)(BIOC +2.8%)(OTCQX:RHHBY +2.2%)(CHEK +20.8%)(TROV +0.6%)
Fri, Apr. 29, 4:12 PM
- Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
- Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
- Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
- Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
- Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
- ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
- Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
- Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
- Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
- Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
- Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
- St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
- Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
- Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
- Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
- Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
- Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
Mon, Apr. 25, 12:47 PM
Mon, Apr. 25, 8:52 AM| Mon, Apr. 25, 8:52 AM | 7 Comments
Mon, Apr. 4, 12:32 PM
- Thinly traded micro cap OncoCyte (OCX +39.8%) is up on almost a 5x surge in volume, albeit on turnover of less than 100K shares, in response to its announcement of a successful 620-subject research study on its lung cancer diagnostic test that validates the transition of the assay platform from Illumina (ILMN +1.3%) microarrays to a Nanostring (NSTG -2.3%) nCounter instrument, the platform OncoCyte intends to use for commercialization. The study, which replicates an earlier one, was conducted by biomedical research organization The Wistar Institute.
- The company will now independently validate the results with its own follow-up study. If successful, it will execute the necessary analytic work to support the test's commercialization. If all goes well, commercial launch could happen in H1 2017. When launched, it will be the first commercially available, non-invasive diagnostic for the early detection of lung cancer.
- The value proposition of liquid biopsy, performed on a peripheral blood sample, is lower cost, greater convenience and much more patient-friendly that traditional tissue biopsy.
- Related tickers: (TROV +2.1%)(TBIO +5%)(SQNM)(CDNA -1.2%)(ILMN +1.3%)(FMI +3%)(BIOC -0.8%)
Tue, Mar. 29, 12:49 PM